This ASX 200 healthcare share just hit a new 52-week high. Here's why

The ASX 200 health imaging company is edging back towards its all-time highs.

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Pro Medicus share price just hit fresh 52-week highs
  • The ASX 200 healthcare share announced a $25 million contract with the University of Washington’s UW Medicine health system
  • Planning for the cloud-based rollout will start immediately

S&P/ASX 200 Index (ASX: XJO) healthcare share Pro Medicus Ltd (ASX: PME) is marching higher today, up 1.51% at the time of writing.

That sees the healthcare stock trading for $63.06 per share after hitting $63.35 late this morning, a fresh 52-week high. It's also now less than 4% below the all-time Pro Medicus share price high, reached in August 2021.

What's sending the ASX 200 healthcare share higher?

Investors are rewarding Pro Medicus after the health imaging company announced on Friday that Visage Imaging, its 100% owned United States subsidiary, signed a $25 million, seven-year contract with the University of Washington's UW Medicine health system.

UW Medicine employs 29,000 healthcare professionals, researchers, and educators.

The ASX 200 healthcare share reported UW Medicine will implement its cloud-engineered Visage 7 Enterprise Imaging Platform throughout its network "providing a unified diagnostic imaging platform".

Planning for the cloud-based rollout will start immediately. Pro Medicus expects the first go-lives to commence in the second half of 2023.

Commenting on the contract, Pro Medicus CEO Sam Hupert said:

UW Medicine joins our growing list of Tier 1 academic clients and will provide us with a strong presence in the Northwest region of the United States. With its highly regarded University of Washington School of Medicine, it has the added benefit of exposing Visage to an ever-increasing number of the doctors of tomorrow.

Hupert noted that the contract encompasses all Pro Medicus Visage products.

"Our pipeline remains strong and spans all market segments," he said. "And as has been the case with many of our recent sales, this deal is for our 'full-stack' comprising all three Visage products namely viewer, workflow and archive, a trend we see continuing."

Pro Medicus share price snapshot

As you can see in the chart below, the Pro Medicus share price strongly outperformed over the past 12 months, gaining 40% compared to a 4% gain posted by the ASX 200.

Investors who bought into the ASX 200 healthcare share five years ago will be sitting on some superbly healthy gains of 683%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

After soaring 40% in 2 weeks, this ASX All Ords healthcare stock has been downgraded

Here’s what analysts at Macquarie rate the stock as now.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Own NIB shares? Here are the key dates for 2026

NIB has released its corporate calendar, including dividend dates, for 2026.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

ASX healthcare stock debuts at a massive discount to its initial public offer price

Saluda Medical shares have had a difficult start to public life, trading well below the initial public offer price.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Healthcare Shares

Why CSL shares now look 'massively oversold'

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which junior biotech's shares are flying on positive trial news?

This company's shares have surged higher after positive clinical trial results for its stroke treatment drug.

Read more »

Excited elderly woman on a swing.
Healthcare Shares

Guess which ASX 300 healthcare share is lifting off on $25 million news

The ASX 300 healthcare share is grabbing investor interest on Thursday. Let’s see why.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Doomed takeover bid for Mayne Pharma to come to an end

The Mayne Pharma takeover saga appears to be finally drawing to an end, with shareholders bearing the pain of the…

Read more »